EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) today announced that David Fineman, KineMed’s Chairman and CEO will present “Leveraging Personal Biology Information for Precision Medicine and Wellness” at the Rodman & Renshaw Annual Global Investment Conference on Tuesday September 10th, from 12:30 to 12:55 EST.
“Leveraging Personal Biology Information for Precision Medicine and Wellness”
In his presentation, Mr. Fineman will share breakthrough results from KineMed’s Kinetic Biomarker platform that demonstrates applications in drug development, diagnostic / therapeutic pairings, and consumer wellness.
“KineMed's kinetic biomarker platform targets the underlying biology and pathways of disease and health. Our assays identify changes in personal biology that provide personalized, real-time information specific to the individual, thus enabling informed decisions for Pharma, Physicians, and Consumers,” said David Fineman, Chairman and CEO of KineMed.
About KineMed, Inc.
KineMed is a commercial stage company that is potentially transformative in drug development, personalized medicine, and wellness. KineMed's kinetic biomarkers of personal biology information guide health-related purchases and drug development decisions, transforming the $18B biomarker, $50B diagnostics, and the >$200B consumer wellness markets. This dynamic information comes from our proprietary mass spectrometric platform, providing the missing link between individuals and optimal health-related products and services in non-prescription wellness management, prescription medical needs, and next generation drug development. These programs provide near-, mid-, and long-term revenues from patients, payors, and developers.
KineMed has developed the first practically useful systems biology technology that can be used directly in humans, with applications not only in drug discovery and development, but also in clinical diagnosis, personalized medicine and therapeutic monitoring, and consumer-wellness decisions. KineMed has three programs based on KineMed’s personal biology information: Rx, Dx/Rx, and Cx:
Therapeutic Drug Discovery and Development (“Rx”)
- Co-development partnerships to improve R&D spend
Prescription diagnostic tests and test/prescription drug pairings
- For prescribing treatments, optimizing dose, predicting drug toxicity, and recommending life-style choices for patients
Non-prescription tests for consumer wellness products (“Cx”)
- Tests that link individuals and product providers to over-the-counter offerings
KineMed’s biomarkers are fully translatable from animal to man across pre-clinical and clinical phases of development. This platform applies to the diagnosis and management of cancers, fibrotic, neurodegenerative, metabolic, and cardiovascular diseases, and consumer wellness.
Over the past few years, KineMed has changed both textbook thought about diseases and the development path of several drug candidates. Notable accomplishments include:
- Developing a “tachometer” of reverse cholesterol transport and metrics of plasma lipid dynamics
- Transforming the pathogenic model of chronic lymphocytic leukemia (CLL)
- Developing the first blood-based biomarker of tissue fibrogenesis in humans
- Generating the first accurate laboratory biomarker of muscle mass in humans
- Creating the first diagnostic tests of disease-modifying processes in a neurodegenerative disease (Parkinson’s Disease)
For more information about KineMed, please visit: http://www.kinemed.com